Personalized Medicine in Actual Practice | GenomeWeb

An article in Forbes reports on new findings that show ImClone Systems' colon cancer drug Erbitux and a similar drug from Amgen, Vectibix, may not work in half of colon cancer patients. By using a genetic test, it can tell patients whether they have tumors with a mutation in kras that would make the drugs ineffective.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.